Pfizer Drug Receives Positive Opinion for Lung Cancer
Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU).
Pfizer Announces Positive Results From Xalkori Trial
Pfizer Inc. announced today that the PROFILE 1007 study demonstrated that XALKORI ( crizotinib ) significantly improved progression-free survival ( PFS ) when compared with pemetrexed or docetaxel , in previously treated patients with anaplastic lymphoma kinase ( ALK )-positive advanced non-small cell lung cancer ( NSCLC ).
FDA Approves Xalkori and Vysis ALK Break Apart FISH Probe Kit
The U.S. Food and Drug Administration today approved Xalkori ( crizotinib ) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers ( NSCLC ) who express the abnormal anaplastic lymphoma kinase ( ALK ) gene.